AIM： To investigate the expression of cyclooxygenase-2 （COX-2） and epithelial growth factor receptor （EGFR） throughout the progression of Barrett＇s esophagus （BE）. METHODS： COX-2 and EGFR protein expressions ...AIM： To investigate the expression of cyclooxygenase-2 （COX-2） and epithelial growth factor receptor （EGFR） throughout the progression of Barrett＇s esophagus （BE）. METHODS： COX-2 and EGFR protein expressions were detected by using immunohistochemical method. A detailed cytomorphological changes were determined. Areas of COX-2 and EGFR expression were quantified by using computer Imaging System. RESULTS： The expressions of both COX-2 and EGFR increased along with the progression from BE to esophagus adenocarcinoma （EAC）. A positive correlation was found between COX-2 expression and EGFR expression. CONCLUSION： COX-2 and EGFR may be cooperative in the stepwise progression from BE to EAC, thereby leading to carcinogenesis.展开更多
目的探讨人参补肺汤合保元汤联合无创正压通气治疗慢性阻塞性肺疾病(Chronic Obstructive Pulmonary Diseases,COPD)肺肾气阴两虚证的临床疗效。方法选取2019年1月—2021年1月期间河南省周口市中医院收治的COPD患者100例,根据患者就诊...目的探讨人参补肺汤合保元汤联合无创正压通气治疗慢性阻塞性肺疾病(Chronic Obstructive Pulmonary Diseases,COPD)肺肾气阴两虚证的临床疗效。方法选取2019年1月—2021年1月期间河南省周口市中医院收治的COPD患者100例,根据患者就诊顺序编号,采用随机数字表法将其分为对照组和观察组,每组各50例。对照组采用无创正压通气治疗,观察组在对照组基础上增加人参补肺汤合保元汤。治疗12周后,观察比较两组患者治疗后临床疗效,比较两组患者治疗前后中医证候积分、肺功能指标[呼气峰值流速(Peak Expiratory Flow,PEF)、第一秒用力呼气量(Forced Expiratory Volume in First Second,FEV1)、第一秒用力呼气量占用力肺活量比率(FEV1/FVC)]、慢性阻塞性肺疾病自我评估测试问卷(COPD Assessment Test,CAT)评分、改良版英国医学研究委员会呼吸问卷(Modified British Medical Research Council,mMRC)评分及无创正压通气时间,同时比较两组患者治疗前后血清基质金属蛋白酶-9(Matrix Metalloproteinase-9,MMP-9)、环氧化酶-2(Cycloxygenase-2,COX-2)及可溶性髓样细胞触发受体-1(Soluble Triggering Receptor Expresses on Myeloid Cells-1,sTREM-1)表达水平及不良反应发生情况。结果治疗后观察组总有效率98.00%(49/50)优于对照组84.00%(42/50),差异有统计学意义(P<0.05)。治疗后两组患者中医证候积分均较治疗前降低,而肺功能指标PEF、FEV1/FVC及FEV1较治疗前升高,差异有统计学意义(P<0.05);且观察组中医证候积分低于对照组,肺功能指标高于对照组,差异有统计学意义(P<0.05)。治疗后两组患者CAT及mMRC评分均较治疗前降低,差异有统计学意义(P<0.05);且观察组CAT及mMRC评分均低于对照组,差异有统计学意义(P<0.05)。治疗后观察组机械通气时间(103.57±10.38)h低于对照组机械通气时间(119.48±11.47)h,差异有统计学意义(P<0.05)。治疗后两组患者MMP-9、COX-2及sTREM-1水平较治疗前降�展开更多
基金Supported by the University of Louisville Hospital the Society for Surgery of the Alimentary Tract Career Development Award
文摘AIM： To investigate the expression of cyclooxygenase-2 （COX-2） and epithelial growth factor receptor （EGFR） throughout the progression of Barrett＇s esophagus （BE）. METHODS： COX-2 and EGFR protein expressions were detected by using immunohistochemical method. A detailed cytomorphological changes were determined. Areas of COX-2 and EGFR expression were quantified by using computer Imaging System. RESULTS： The expressions of both COX-2 and EGFR increased along with the progression from BE to esophagus adenocarcinoma （EAC）. A positive correlation was found between COX-2 expression and EGFR expression. CONCLUSION： COX-2 and EGFR may be cooperative in the stepwise progression from BE to EAC, thereby leading to carcinogenesis.
文摘目的探讨人参补肺汤合保元汤联合无创正压通气治疗慢性阻塞性肺疾病(Chronic Obstructive Pulmonary Diseases,COPD)肺肾气阴两虚证的临床疗效。方法选取2019年1月—2021年1月期间河南省周口市中医院收治的COPD患者100例,根据患者就诊顺序编号,采用随机数字表法将其分为对照组和观察组,每组各50例。对照组采用无创正压通气治疗,观察组在对照组基础上增加人参补肺汤合保元汤。治疗12周后,观察比较两组患者治疗后临床疗效,比较两组患者治疗前后中医证候积分、肺功能指标[呼气峰值流速(Peak Expiratory Flow,PEF)、第一秒用力呼气量(Forced Expiratory Volume in First Second,FEV1)、第一秒用力呼气量占用力肺活量比率(FEV1/FVC)]、慢性阻塞性肺疾病自我评估测试问卷(COPD Assessment Test,CAT)评分、改良版英国医学研究委员会呼吸问卷(Modified British Medical Research Council,mMRC)评分及无创正压通气时间,同时比较两组患者治疗前后血清基质金属蛋白酶-9(Matrix Metalloproteinase-9,MMP-9)、环氧化酶-2(Cycloxygenase-2,COX-2)及可溶性髓样细胞触发受体-1(Soluble Triggering Receptor Expresses on Myeloid Cells-1,sTREM-1)表达水平及不良反应发生情况。结果治疗后观察组总有效率98.00%(49/50)优于对照组84.00%(42/50),差异有统计学意义(P<0.05)。治疗后两组患者中医证候积分均较治疗前降低,而肺功能指标PEF、FEV1/FVC及FEV1较治疗前升高,差异有统计学意义(P<0.05);且观察组中医证候积分低于对照组,肺功能指标高于对照组,差异有统计学意义(P<0.05)。治疗后两组患者CAT及mMRC评分均较治疗前降低,差异有统计学意义(P<0.05);且观察组CAT及mMRC评分均低于对照组,差异有统计学意义(P<0.05)。治疗后观察组机械通气时间(103.57±10.38)h低于对照组机械通气时间(119.48±11.47)h,差异有统计学意义(P<0.05)。治疗后两组患者MMP-9、COX-2及sTREM-1水平较治疗前降�
